Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo aims to halt aggressive prostate cancer

NCT ID NCT05826509

First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 25 times

Summary

This study tests whether adding the drug darolutamide to surgery can delay the return or spread of high-risk prostate cancer. About 240 men will either have surgery alone or surgery plus darolutamide taken before and after the operation. The goal is to see if the combination keeps the cancer from becoming incurable longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHU Bordeaux

    Bordeaux, France

  • CHU Grenoble

    Grenoble, France

  • CHU Lyon - Hôpital Edouard Herriot

    Lyon, France

  • CHU Lyon - Sud

    Pierre-Bénite, France

  • CHU Rennes

    Rennes, France

  • CHU Toulouse

    Toulouse, France

  • Chu Angers

    Angers, France

  • Chu Henri Mondor

    Créteil, France

  • Chu Tours - Hopital Bretonneau

    Tours, France

  • Clinique La Croix Du Sud

    Quint-Fonsegrives, France

  • Hopital Claude Huriez

    Lille, France

  • Hopital Europeen Georges-Pompidou

    Paris, France

  • Hopital Foch

    Suresnes, France

  • Hopital Paris Saint-Joseph

    Paris, 75014, France

  • Hopital Pitie Salpetriere

    Paris, France

  • Institut Bergonié

    Bordeaux, France

  • Institut Mutualiste Montsouris

    Paris, France

  • Institut Paoli-Calmettes

    Marseille, France

  • Institut Universitaire Du Cancer Toulouse - Oncopole

    Toulouse, France

Conditions

Explore the condition pages connected to this study.